ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
The impact of residual tricuspid regurgitation on long-term clinical outcomes, following tricuspid transcatheter edge-to-edge repair.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuccess of tricuspid transcatheter edge-to-edge repair (T-TEER) was defined in feasibility studies for specific devices by ≥ one-grade tricuspid regurgitation (TR) reduction (1 + to 5 + classification). However, the Clinical Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System (TRILUMINATE) randomized controlled trial (RCT) showed significant quality of life (QoL) improvement only in patients with residual moderate-or-less TR (MTR). We sought to validate this finding in a real-world cohort by comparing long-term T-TEER clinical outcomes between patients with residual severe TR (STR; 3 +) and those with MTR (≤ 2).
methodsEligible inoperable patients had symptomatic functional TR despite medical therapy. The primary efficacy endpoint was ≥ one-grade TR reduction, coupled with severe-or-less residual TR (≤ 3), by 30-day follow-up.
resultsSixty-four patients (mean-age 81.8 ± 4.9 years; STS Score 10 ± 5.1%; 92% NYHA III-IV) with ≥ 3 TR underwent T-TEER at our institution. The primary efficacy endpoint was 94% (60/64) (37 MTR vs 23 STR patients), with 100% technical success. Both MTR (n = 32) and STR (n = 21) 1-year survivors improved their QoL, e.g., KCCQ Score increased by 33.7 ± 15.5 pts. (p < 0.001) vs 23 ± 16.1 pts. (p = 0.001) (between-group p = 0.166), with no significant difference in NYHA class reduction (one-grade 56% vs 62%, p = 1.000; two-grade 31% vs 19%, p = 0.544). Predictors of STR on multivariate analysis were periprocedural image quality (OR 1.90, p = 0.003) and main TR jet position (OR 1.55, p = 0.036).
conclusionsAlthough T-TEER should instinctively aim for MTR, considerable reduction is not always possible in multimorbid patients with advanced right heart remodeling. This study indicates that even moderate TR reduction and residual STR can improve QoL. Therefore, echocardiography should not be the only indicator of success.
Indexed as
Identifiers
42113216What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.